From the Infectious Diseases Unit, Royal Children's Hospital, Melbourne, Victoria, Australia, Blantyre, Malawi.
Malawi-Liverpool Wellcome Trust Research Programme.
Pediatr Infect Dis J. 2022 Mar 1;41(3S):S10-S17. doi: 10.1097/INF.0000000000003317.
Antimicrobial stewardship (AMS) is central to the World Health Organisation Global Action Plan against antimicrobial resistance (AMR). If antibiotics are used without restraint, morbidity and mortality from AMR will continue to increase. In resource-rich settings, AMS can safely reduce antibiotic consumption. However, for children in low- and middle-income countries (LMIC), the impact of different AMS interventions is unknown.
To determine the impact of different AMS interventions on antibiotic use and clinical and microbiologic outcomes in children in LMIC.
MEDLINE, Embase and PubMed were searched for studies of AMS interventions in pediatric population in LMIC settings. Controlled trials, controlled before-and-after studies and interrupted time series studies were included. Outcomes assessed were antibiotic use, multidrug-resistant organism (MDRO) rates, clinical outcomes and cost.
Of 1462 studies, 34 met inclusion criteria including a total population of >5,000,000 in 17 countries. Twenty were in inpatients, 2 in ED, 10 in OPD and 2 in both. Seven studies were randomized controlled trials. All types of interventions reported a positive impact on antibiotic prescribing. AMS bundles with education, and clinical decision tools appeared more effective than guidelines alone. AMS interventions resulted in significantly decreased clinical infections (4/4 studies) and clinical failure (2/2) and reduced MDRO colonization rate (4/4). There was no concomitant increase in mortality (4/4 studies) or length of stay (2/2).
Multiple effective strategies exist to reduce antibiotic consumption in LMIC. However, marked heterogeneity limit conclusions regarding the most effective approach, particularly regarding clinical outcomes. Overall, AMS strategies are important tools in the reduction of MDRO-related morbidity in children in LMIC.
抗菌药物管理(AMS)是世界卫生组织对抗抗菌药物耐药性(AMR)全球行动计划的核心。如果不加限制地使用抗生素,AMR 导致的发病率和死亡率将继续上升。在资源丰富的环境中,AMS 可以安全地减少抗生素的使用。然而,对于中低收入国家(LMIC)的儿童,不同 AMS 干预措施的影响尚不清楚。
确定不同 AMS 干预措施对 LMIC 儿童抗生素使用以及临床和微生物学结局的影响。
检索 MEDLINE、Embase 和 PubMed 中关于 LMIC 环境中儿科人群 AMS 干预措施的研究。纳入了对照试验、对照前后研究和中断时间序列研究。评估的结局包括抗生素使用、多药耐药菌(MDRO)率、临床结局和成本。
在 1462 项研究中,有 34 项符合纳入标准,包括 17 个国家的>500 万人口。其中 20 项为住院患者,2 项为急诊,10 项为门诊,2 项为两者兼有。有 7 项研究为随机对照试验。所有类型的干预措施均报告对抗生素处方有积极影响。带教育和临床决策工具的 AMS 综合干预措施比单独使用指南更有效。AMS 干预措施显著降低了临床感染(4/4 项研究)和临床失败(2/2 项)的发生率,并降低了 MDRO 定植率(4/4 项)。没有同时增加死亡率(4/4 项研究)或住院时间(2/2 项)。
在 LMIC 中存在多种有效的策略来减少抗生素的使用。然而,明显的异质性限制了对最有效方法的结论,特别是对临床结局。总的来说,AMS 策略是减少 LMIC 儿童与 MDRO 相关发病率的重要工具。